Icosavax Revenue and Competitors
Estimated Revenue & Valuation
- Icosavax's estimated annual revenue is currently $7.3M per year.
- Icosavax's estimated revenue per employee is $111,364
- Icosavax's total funding is $161M.
- Icosavax's current valuation is $644.6M. (January 2022)
Employee Data
- Icosavax has 66 Employees.
- Icosavax grew their employee count by 14% last year.
Icosavax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 200% | N/A | N/A |
#2 | $1.1M | 7 | -36% | N/A | N/A |
#3 | N/A | 33 | 10% | N/A | N/A |
#4 | $4.8M | 31 | 19% | N/A | N/A |
#5 | N/A | 30 | 43% | N/A | N/A |
#6 | $1.3M | 15 | -6% | N/A | N/A |
#7 | N/A | 29 | 93% | N/A | N/A |
#8 | $31.6M | 146 | 23% | $30.2M | N/A |
#9 | $1.9M | 12 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -16% | N/A | N/A |
What Is Icosavax?
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
keywords:N/A
$161M
Total Funding
66
Number of Employees
$7.3M
Revenue (est)
14%
Employee Growth %
$644.6M
Valuation
N/A
Accelerator
Icosavax's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Global Program Management | |
2 | VP, Clinical Operations | |
3 | VP, Clinical Development - Research and Development | |
4 | SVP Technical Operations | |
5 | Senior Clinical Operations Manager | |
6 | Senior Scientist | |
7 | VP, Quality | |
8 | CSO | |
9 | Director Drug Substance Operations | |
10 | VP Preclinical Development |
Icosavax News
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with...
Icosavax expects to announce interim results for its RSV vaccine candidate in Q2. If those results are positive, the company plans to move...
Icosavax has reported topline interim data from the Phase I/II IVX-411-01 clinical trial of its virus-like particle (VLP) vaccine candidate,...
The field of companies pursuing a vaccine for respiratory syncytial virus (RSV) includes several pharmaceutical giants with plenty of resources and cash to pour into research. The scientists at four-year-old Icosavax believes their company’s technology could set it apart and the biotech now has ...
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax Photo) Seattle-based Icosavax has filed to go public via an IPO, just four years after it launched out of the University of Washington. The company, a spin ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.1M | 66 | -45% | N/A |
#2 | $7.5M | 66 | 0% | N/A |
#3 | $8.3M | 66 | -15% | N/A |
#4 | $16M | 66 | 5% | N/A |
#5 | $12.5M | 66 | -8% | N/A |